Chor Cheung Tam

Dr. Chor Cheung Tam

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
CTChor Cheung Tam
Chor Cheung Tam
KCKent-Shek Cheung
Kent-Shek Cheung
SLSimon Lam
Simon Lam
AWAnthony Wong
Anthony Wong
AYArthur Yung
Arthur Yung
CSChung-Wah Siu
Chung-Wah Siu

1 November 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KCKwong-Yue Eric Chan
Kwong-Yue Eric Chan
DCDaniel Tai-Leung Chan
Daniel Tai-Leung Chan
CLCheung-Chi Simon Lam
Cheung-Chi Simon Lam
MSMichael Shu-Yue Sze
Michael Shu-Yue Sze
KUKa-Chun Un
Ka-Chun Un
CWChun Ka Wong
Chun Ka Wong

5 May 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
CTChor Cheung Tam
Chor Cheung Tam
KCKent‐Shek Cheung
Kent‐Shek Cheung
SLSimon Lam
Simon Lam
AWAnthony Wong
Anthony Wong
AYArthur Yung
Arthur Yung
CSChung‐Wah Siu
Chung‐Wah Siu

22 December 2016 in Journal of International Medical Research
Verified
Journal Article
Open access
CTChor Cheung Tam
Chor Cheung Tam
JKJanette Kwok
Janette Kwok
AWAnthony Wong
Anthony Wong
AYArthur Yung
Arthur Yung
CSCatherine Shea
Catherine Shea
SLStephen Lee
Stephen Lee
Objective: The CYP2C19 loss-of-function (LoF) allele is present in half of the East Asian population and is associated with high on-treatment platelet reactivity (HTPR). This study aimed to investigate whether a rapid genotyping-guided approach is feasible and efficacious for selecting P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome (ACS). Methods: This was a single-centre, prospective, randomized, open-label study. A total of 132 patients with ACS were randomized to the rapid genotyping-guided treatment group (GG, N = 65) or the standard treatment group (SG, N = 67). Patients in the GG group were genotyped by the Verigene system. Patients with the CYP2C19 LoF allele were switched to ticagrelor and all remaining patients continued on clopidogrel. The endpoints were HTPR at 24 hours after the first loading dose of clopidogrel and 1 month afterwards. Results: Forty patients in the GG group switched to ticagrelor, while others continued on clopidogrel. The incidence of HTPR in the GG vs SG groups was 9.2% vs 40.3% at 24 hours and 6.5% vs 32.3% at 1 month, respectively. Rapid point-of-care genotyping showed 100% concordance with conventional genotyping by real-time polymerase chain reaction. Conclusions: In Chinese patients suffering from ACS, the rapid genotyping-guided approach for selecting P2Y12 receptor blockers is feasible and reduces the incidence of HTPR. Clinical Trial Registration: URL: http://clinicaltrials.gov . Unique identifier: NCT01994941.

5 December 2023 in JACC: Asia
Verified
Journal Article
Open access
IHIsaac Ho
Isaac Ho
CWChun-Ka Wong
Chun-Ka Wong
YWYuen-Kwun Wong
Yuen-Kwun Wong
TLTsun-Ho Lam
Tsun-Ho Lam
ILIsaac Sze-Him Leung
Isaac Sze-Him Leung
HTHung-Fat Tse
Hung-Fat Tse
Previous studies suggest that aromatase inhibitors (AIs) increase the risk of adverse cardiovascular events and cardiac arrhythmias in patients with breast cancer, but it is unclear whether AIs also increase the risk of new-onset atrial fibrillation (AF). The purpose of this study was to investigate whether the use of AIs was associated with an increased risk of new-onset AF in patients with breast cancer. We performed a retrospective analysis involving 5,707 patients with breast cancer (mean age 63.9 ± 11.2 years and 99.9% women) who received adjunctive hormone therapy with an AI (AI group, n = 4,878) or tamoxifen (tamoxifen group, n = 829) in Hong Kong between January 1, 1999, and December 31, 2020. After propensity score matching, there were 1,658 and 829 patients with balanced characteristics in the AI group and tamoxifen group, respectively. After 8,863 patient-years of follow-up, patients who were prescribed AI had a trend toward more new-onset arrhythmias compared with those prescribed tamoxifen (0.62 vs 0.30 per 100 patient-years; crude HR: 2.05; P = 0.053). The difference in arrhythmic risk was mainly driven by a higher incidence rate of new-onset AF in the AI group (0.59 vs 0.27 per 100 patient-years; crude HR: 2.18; P = 0.046). The use of AIs was confirmed to be an independent risk factor for new-onset AF on multivariate analysis (adjusted HR: 2.75; P = 0.01). Among breast cancer patients prescribed adjunctive hormonal therapy, AI was associated with an increased risk of new-onset AF. Regular surveillance for new-onset AF should be considered in breast cancer patients treated with an AI.

31 July 2017 in Journal of International Medical Research
Verified
Journal Article
Open access
CTChor Cheung Tam
Chor Cheung Tam
KCKelvin Chan
Kelvin Chan
SLSimon Lam
Simon Lam
AYArthur Yung
Arthur Yung
YLYui Ming Lam
Yui Ming Lam
HTHung-Fat Tse
Hung-Fat Tse
Objective: To evaluate the 1-year clinical outcomes of patients who received the Resolute Onyx™ stent. Methods: This was a single-centre, retrospective registry analysis that reviewed the clinical data from all patients who were implanted with a Resolute Onyx™ stent between March 2015 and February 2016. Clinical follow-up was performed at 1 year post-implantation. Results: A total of 252 patients received a Resolute Onyx™ stent and two patients were lost to follow-up. The mean age of the cohort was 66.9 years and 113 (45.2%) had diabetes mellitus. Thirty-eight patients (15.2%) had left main disease and 73 (29.2%) had three-vessel disease. A total of 175 patients (70.0%) had small vessel disease (20 mm). The 1-year target lesion failure was 4.4% (11 of 250), cardiovascular death occurred in eight patients (3.2%), ischaemia-driven target lesion revascularization was undertaken in five patients (2.0%) and stent thrombosis occurred in one patient (0.4%). Conclusion: The Resolute Onyx™ stent showed a favourable 1-year clinical performance in a real-world population.